Edmonton, Alberta, Canada
June 8, 2009
The Pest Management Regulatory
Agency of Health Canada has granted
Innovotech (TSV
VENTURE:IOT) a Research Authorization for large-scale field
trials for the 2009 season to test its novel seed treatment,
Agress™.
This Research Authorization provides growers with an opportunity
to assess the real-world ability of Agress™ to fight bacterial
disease and its ease of use. In conjunction with cooperating
growers, dry beans treated with Agress™ have been planted on
farms in Alberta.
"These large-scale field trials give us an opportunity to test
Agress™ on a commercial scale that would be used by a grower,"
says Damian Sowa, Product Manager, Innovotech. "We will also use
the trials to validate our small plot results that showed
Agress™ to be a superior and long sought replacement for
Streptomycin in bacterial infestations of beans."
Research is currently underway to expand the applications of
Agress™ to include the major crops in North America and
additional disease classes.
Innovotech is a product development company focusing on the
development of solutions to medical, agricultural and industrial
problems caused by microbial biofilms. Biofilms are protected
communities of microorganisms which are very common and very
difficult to treat due to their inherent resistance. The company
currently has two products in advanced stages of development:
bioFILM PA is a diagnostic kit which assists physicians in the
selection of the most effective antibiotic treatment of patients
with chronic lung infections. Agress™ is a novel seed
treatment product which protects seeds during the critical
germination and emergence stage from bacterial and fungal
infection. Both products were developed against the
corresponding organisms present as biofilms as opposed to the
free-floating, planktonic form. |
|
